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Abstract
Background
Modeling trajectories of decline can help describe the variability in progression of cognitive
impairment in dementia. Better characterisation of these trajectories has significant implica-
tions for understanding disease progression, trial design and care planning.
Methods
Patients with at least three Mini-mental State Examination (MMSE) scores recorded in the
South London and Maudsley NHS Foundation Trust Electronic Health Records, UK were
selected (N = 3441) to form a retrospective cohort. Trajectories of cognitive decline were
identified through latent class growth analysis of longitudinal MMSE scores. Demographics,
Health of Nation Outcome Scales and medications were compared across trajectories
identified.
Results
Four of the six trajectories showed increased rate of decline with lower baseline MMSE.
Two trajectories had similar initial MMSE scores but different rates of decline. In the faster
declining trajectory of the two, a higher incidence of both behavioral problems and sertraline
prescription were present.
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Conclusions
We find suggestive evidence for association of behavioral problems and sertraline prescrip-
tion with rate of decline. Further work is needed to determine whether trajectories replicate
in other datasets.
Introduction
Patients with dementia differ from one another in how quickly they deteriorate in cognition
[1]. It is likely that a number of different factors contribute to this observed heterogeneity in
disease progression, the extent of which is not fully understood.
A number of approaches have previously been used to study trajectories of dementia-
related decline. A quadratic path of decline has been proposed in studies following subjects
with either pre-clinical dementia [2] or late onset Alzheimer’s disease (AD) [3] and mixed
effects models have been used to describe some of the heterogeneity through inclusion of sub-
ject-level random effects. These random effects allow for individual-level trajectories around a
mean path of decline. Such models have also been used to explore risk factors for cognitive
decline [4–7]. Another approach is to group subjects into fast and slow decline categories [1,
8]. However, it is possible that multiple dementia sub-populations exist with different patterns
of decline [3, 9].
In latent class growth analysis, individuals are grouped together according to their pattern
of change in outcome over time [10]. When applied to cognitive assessments, trajectories of
decline emerge, which may be due to unrecognized sub-populations and could reflect different
underlying processes of progression. Once such trajectory memberships have been defined
we can describe these sub-populations and test the ability of characteristics to discriminate
between trajectory classes and predict trajectory membership. Indeed, this technique has been
used previously to demonstrate the association of cognitive decline with amyloid-beta and
Apolipoprotein E (APOE) e4 status in healthy older adults [11].
To understand between-subject differences in cognitive decline, we need to characterise the
effect of medications and comorbidities with deterioration. For example, presence of psychosis
in AD, longstanding depressive symptoms, anxiety, and antidepressant and antipsychotic
medications may all affect the deterioration of cognition [12, 13].
A key challenge in these studies is to identify longitudinal cohorts of sufficient size and
length of follow up to reflect the path of progression for dementia patients. The South London
and Maudsley NHS Foundation Trust (SLaM) has made its pseudonymised electronic health
record (EHR) available for research through the Clinical Record Interactive Search (CRIS)
application [14]. The records include repeat Mini-Mental State Examination scores (MMSE)
available from memory assessments, as well as patient demographics, medications and comor-
bidities. Previously, a 6 to 12 month window of efficacy of acetyl cholinesterase inhibitors was
revealed in these records, demonstrating their usefulness for research [15]. This wealth of
information provides an opportunity to study heterogeneity in cognitive decline and variables
contributing to decline in a real world setting.
In this study, latent class growth analysis was applied to identify trajectories of cognitive
decline in routinely collected EHRs from SLaM. Characterisation of the sub-populations iden-
tified highlighted factors associated with the observed pattern of decline.
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PLOS ONE | https://doi.org/10.1371/journal.pone.0178562 June 7, 2017 2 / 18
Funding: This study presents independent
research part funded by Janssen pharmaceuticals
and the National Institute for Health Research
(NIHR) Biomedical Research Centre and Dementia
Unit at SLaM NHS Foundation Trust and King’s
College London. The views expressed are those of
the author(s) and not necessarily those of the NHS,
the NIHR or the Department of Health. RJBD & SN
were supported by awards to establish the Farr
Institute of Health Informatics Research, London,
from the Medical Research Council, Arthritis
Research UK, British Heart Foundation, Cancer
Research UK, Chief Scientist Office, Economic and
Social Research Council, Engineering and Physical
Sciences Research Council, National Institute for
Health Research, National Institute for Social Care
and Health Research, and Wellcome Trust (grant
MR/K006584/1), as well as the National Institute
for Health Research University College London
Hospitals Biomedical Research Centre. SLaM CRIS
is supported by the NIHR Biomedical Research
Centre for Mental Health BRC Nucleus at the SLaM
NHS Foundation Trust and Institute of Psychiatry,
King’s College London jointly funded by the Guy’s
and St Thomas’ Trustees and the SLaM Trustees.
The funders had no role in study design, data
collection and analysis, decision to publish, or
preparation of the manuscript.
Competing interests: Elizabeth Baker is funded by
Janssen Pharmaceuticals. The CRIS team (HS, MB
and RS) have received research funding from
Roche, Pfizer, Johnson & Johnson and Lundbeck.
The other authors declare no competing interests.
There are no patents, products in development or
marketed products to declare. This does not alter
our adherence to all the PLOS ONE policies on
sharing data and materials.
Materials and methods
Sample
Our retrospective patient cohort was derived from the South London and Maudsley NHS
Foundation Trust (SLaM) Clinical Record Interactive Search (CRIS) tool described previously
by Stewart et al[16]. The retrospective cohort was designed to make secondary use of EHR
data for the study of cognitive decline. Specifically, to explore trajectories of progression in
patients who were being assessed for dementia and who were likely to receive a dementia diag-
nosis during follow up. This was achieved by including a) subjects who had received their first
referral to older adults mental health services between January 2007 and December 2014 and
b) had at least three MMSE scores recorded after the first referral date and in this same period,
reflecting continued assessment for dementia. Our study was therefore able to explore changes
in cognition as new cases of dementia emerge.
As no selection was made based on diagnosis, primary diagnoses received at any point
during the patient journey were extracted, including dementia diagnoses; (mild cognitive
impairment (MCI), Alzheimer’s disease (AD), vascular dementia (VD), Lewy body dementia
(LBD) and frontotemporal dementia (FTD)) and others (depression, psychosis and psychotic
symptoms, behavioral disturbances, bipolar disorder and schizophrenia) were collected. MCI
is included as a dementia diagnosis to identify those with some uncertainty in diagnosis but
with cognitive impairment that may lead to dementia, suggesting they are in a period of
transition.
Diagnoses were recorded at multiple time points throughout the patient journey and
included both primary diagnoses recorded with ICD-10 code and from discussions of primary
diagnoses in free text from patient health records. ICD-10 provides guidance on diagnosing
dementia, including observation of cognitive decline, information on medical history of the
patient and measuring brain atrophy. However, diagnosis decisions are likely to vary with cli-
nician practice and may rely on cognitive testing and medical history alone.
Diagnosis information was used to inform whether sub-type specific trajectories were
observed.
Data extraction. Structured field derived information included year of birth, gender, eth-
nicity, retirement status, cohabiting status and Health of the Nation Outcome Scales (HoNOS)
item scores. MMSE scores, primary diagnoses, medications and age left school had previously
been extracted from structured fields and free text using General Architecture for Text Engi-
neering (GATE) applications, the chosen natural language processing software for use in CRIS
[14]. Details on the performance of these applications have been reported previously[16].
Cognitive outcome. Mini-mental state examinations are widely used by clinicians to
assess the level of cognitive impairment and cognitive decline in patients undergoing assess-
ment for dementia. This scale has been validated in a number of populations[17, 18]. These
scores are the only measure available to explore cognitive change in these electronic health rec-
ords and are typically recorded here as total score with numerator and denominator without
individual sub-scores.
During the assessment of cognitive impairment using MMSE, a series of questions are
asked relating to temporal and spatial orientation, memory, attention, language and visuospa-
tial functions. A maximum of 30 points can be achieved. Questions could be missed because of
long-standing health problems such as hearing impairments, resulting in a denominator less
than 30. Observations with a denominator less than 20 were excluded. For the 7% of scores
with denominators less than 30 the numerator was weighted by the ratio denominator/30.
In some records two MMSE scores appeared on the same date but with different values.
The majority of these scores differed by +/- one to two points. Without further information on
Disease progression trajectories in dementia
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the most accurate score and to avoid bias in selection of values, the first recorded MMSE value
was selected.
In clinical practice, MMSE scores are recorded at different times for each individual and
follow-up is closely related to service use and health of the individual. In our sample, MMSE
observations were made during a median follow up period of 1.70 years (IQR 0.79 to 2.99
years). 41% of individuals died during follow-up, with median time to death 3 years (IQR
1.76–4.53).
Demographics. Demographics extracted included gender, ethnicity, cohabiting status,
retirement status and age of leaving formal education. Year of birth rather than date of birth is
retained within the health records as part of the record pseudonymisation process. Age at first
MMSE was therefore calculated from year of birth. Cohabiting and retirement status, repre-
senting lifestyle differences, were derived from marital status and employment status. Age of
leaving formal education was used as an indicator for educational achievement, as higher edu-
cational attainment is thought to reflect greater cognitive reserve against onset of decline [19].
Health indicators. HoNOS are used to assess a range of outcomes in older adults with
mental health problems[20]. HoNOS consist of 12 items including; behavioral disturbances,
non-accidental self-injury, drink or drug abuse, cognitive problems, physical health or disabil-
ity, hallucinations or delusions, depressive symptoms, other mental and behavioral problems,
social or supportive relationships, activities of daily living (ADL), living situation and work
and leisure activities. Each item is rated according to severity of the problem as determined by
the clinician; None, Minor, Mild (intervention required), Moderate or Severe. Moderate and
severe categories were combined due to the small proportion of subjects rated as severe. Scores
closest to the date of the first recorded MMSE score were selected as baseline HoNOS scores.
No limit was imposed on the time between the first MMSE score and HoNOS score. Time to
HoNOS scores is reported below.
Medications. Dementia medications and medications a) whose use has been suggested as
repurposed agents in dementia in Appleby et al 2013 [21], and b) are prescribed within the UK
mental health care setting. The complete list of medications extracted can be found in S1
Table. Episodes of medication use are defined by prescription start and stop dates. Successive
medications prescription dates within 42 days are defined as single episodes to reflect periods
of repeat prescriptions. Subjects were considered on medication at baseline if the medication
episode was 6 months pre or post the date of the first MMSE. Any medications prescribed to
less than 1% of the sample were excluded from analysis.
Statistical analysis
Identifying trajectories of cognitive decline. Baseline was the time of the first received
MMSE score. Latent class growth analysis (LCGA) was used to identify trajectories of decline
in repeated MMSE scores[10]. Years since first MMSE score was used as the time variable.
Both linear and quadratic terms were included. A quadratic term appeared sufficient to model
the non-linear trend in the data and other more flexible models, including splines were not
considered. LCGA was performed using the flexmix package in R [22]. Time in years was cen-
tered to allow for interpretation of both linear and quadratic terms.
Unconditional LCGA models testing the number of trajectory classes (k) 1–10 were com-
pared by Bayesian Information Criteria (BIC) and bootstrapped likelihood ratio test (BLRT)
[23]. Best fitting models are reflected in low relative BIC and significant improvements in k
over k-1 trajectory models as indicated by the BLRT p value < 0.05. Each subject was assigned
to the class with the maximum posterior probability for subsequent analysis. Relative entropy
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(entropy information criterion (EIC))[24] was reported indicating class separation for each
trajectory model.
Descriptive analysis. Global associations between baseline variables and trajectory classes
were investigated using Kruskal-Wallis chi-square tests (K-W χ2) and Chi-square tests (χ2) (or
Fisher’s exact for low frequencies). Multivariable multinomial logistic regression analysis was
performed to describe the relationship between trajectory membership and baseline character-
istics. A final model was chosen based on stepwise selection of variables showing statistical sig-
nificance in the above tests using AIC. Our association testing occurs within a single model
but the number of covariates and trajectories means a large number of comparisons were
made (>100), increasing our type I error rate [25]. False Discovery Rate was used to adjust p-
values [26] and the quantile for computing confidence intervals was adjusted by the propor-
tion of significant observations to give adjusted confidence intervals[27].
Baseline prediction model. Support Vector Machine (SVM) Models were developed to
investigate baseline characteristics that could predict trajectory membership for trajectories
that were not confounded by disease stage. SVMs with Linear, Polynomial and Radial Basis
Kernel Functions were tested within the R caret package [28]. Data was split into 80%: 20%
training to test set. Class imbalance can lead to a learning bias towards the majority class. The
training data was sampled to give an equal proportion of individuals from each trajectory. The
test data was not modified to reflect prediction in the real world setting. To avoid undue influ-
ence of predictors with large numeric ranges, all categorical variables were split into binary
variables and continuous variables were centered and scaled. For the HoNOS items, the rating
of “none” was used as the reference category. Recursive feature elimination (RFE) using
10-fold cross-validation on the training data was repeated 5 times to select the optimal subset
of predictors. Near-zero variance predictors were removed prior to RFE whilst variables were
centered and scaled during RFE. Parameters for linear, polynomial and radial-basis kernel
functions were tuned by 10-fold cross-validation during RFE and can be found in S2 Table.
Parameter tuning was performed on the whole training data with predictors selected in RFE
using 10-fold cross validation, repeated 5 times. The model with the highest accuracy was
selected. Sensitivity, Specificity and Receiver Operator Curve—Area Under the Curve (AUC)
were calculated to assess model performance on the test set.
Diagnosis across trajectories. We compared proportions of diagnoses received during
follow up in each trajectory using either χ2 or Fisher’s tests to compare whether different diag-
noses related to trajectories observed.
Results
Cohort characteristics
In our patient population (n = 3441), the majority was female (gender: 62% female, 38% male)
and was of white ethnicity (78% white, 15% black, 4% Asian, 2% Other). The median age at
baseline was 80 years (IQR 74 to 85) and median MMSE of 22 (IQR 19 to 26) at baseline. Fol-
low up was over a median of 1.70 years (IQR 0.79 to 2.99 years).
To evaluate how close the medication episodes and HoNOS items scores occurred with
respect to our defined baseline, proportion of observations occurring before or after the first
MMSE date i.e. baseline were identified. Medication episodes were included if they occurred
in the period from 6 months before to 6 months after baseline. 18% of medication episodes
occurred on or included baseline. 13% of medication episodes occurred between 0 and 6
months before baseline. For these 13%, medication episodes ended a mean of 34 days (SD 43
days) and median of 15 days before baseline. 69% of episodes occurred between 0 and 6
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months after baseline. With the episode start date occurring a mean of 41 days (SD 51 days)
and median of 15 days after baseline.
For the HoNOS item scores,42% of scores occurred 0 and 3.6 years before baseline,. The
mean time in days from HoNOS score to baseline was 14 days (SD 49) and a median of 5 days.
For the 58% of scores occurring after between 0 and 4 years from baseline; the scores occur a
mean of 43 days (SD 129 days) from baseline with a median of 1 day.
Trajectories of decline
We tested how many trajectories of cognitive decline were optimal to explain the heterogeneity
in the MMSE scores in this patient population. We identified the LCGA model with six trajec-
tories as the optimal model (Table 1). The BIC was lowest for the model with nine trajectories;
however, the BLRT indicated no further significant improvement in model fit after including
six trajectories, so the six-trajectory model was selected (Table 1). The EIC (Table 1) suggested
acceptable class separation for the model. Average and individual level MMSE profiles are pre-
sented in Figs 1 and 2 and trajectory parameters estimated in the six-trajectory model are
observed in Table 2.
The majority of subjects were in trajectories 2, 3 and 5 (22%, 22% and 18%, respectively).
Fewer subjects were assigned to trajectory 6 and 4 (14% and 9%), with the fastest rate of
decline. 14% of subjects were assigned to the stable trajectory 1.
The trajectories identified differ in baseline MMSE score, with the lower baseline MMSE
score having faster decline (Fig 1). An exception to this is trajectory 4, which had similar base-
line MMSE score to trajectory 3 but a more similar rate of decline to trajectory 6.
Trajectory sub-population characteristics. Next we describe properties of patients
within the trajectories in relation to demographics, baseline MMSE, HoNOS items and
medications.
Global comparative tests highlighted differences in age (K-W χ2-statistic = 180.67, p-value
(p)< 0.0001), baseline MMSE score (K-W χ2-statistic = 2311, p< 0.0001), gender (χ2–statis-
tic = 21.7, degrees of freedom (df) = 5, p = 0.00059), age left school (χ2–statistic = 102, df = 20,
p< 0.0001) and ethnicity (χ2–statistic = 31.8, df = 15, p = 0.00687) were found across trajecto-
ries (S3 Table).
HoNOS items that were found to be differentially represented across the trajectories
included problems related to behavioral disturbance (Fisher’s exact p-value (p) = 0.0005), non-
accidental self-injury (p = 0.0005), cognitive problems (p = 0.0005), physical health or disabil-
ity (χ2–statistic = 34, df = 15, p = 0.00329), hallucinations or delusions (p = 0.0005), depressive
symptoms (p = 0.0005), other mental or behavioral problems (χ2–statistic = 59.8, df = 15,
p< 0.001), social or supportive relationships (p = 0.031), ADL (χ2–statistic = 340, df = 15,
p< 0.001) and work and leisure activities (χ2 –statistic = 78, df = 15, p< 0.001) (S4 Table).
Differentially represented medications included donepezil (χ2–statistic = 121, df = 5,
p< 0.0001), memantine (p = 0.0005), rivastigmine (p = 0.001), amlodipine (χ2-statistic = 12.28,
df = 5, p = 0.031), citalopram (χ2-statistic = 15.2, df = 5, p = 0.01), fluoxetine (p = 0.01), sertra-
line (p = 0.001), olanzapine (p = 0.0005) and risperidone (p 0.0075) (S5 Table).
We performed multinomial logistic regression analysis, to identify baseline characterisitcs
associated with trajectory membership. We selected trajectory 4 as the reference trajectory as
firstly it does not follow a pattern of lower intercept and faster decline. Secondly, it has similar
baseline MMSE score to trajectory 3 but faster decline. Comparisons to trajectory 4 may there-
fore highlight characteristics that may explain differences in rate of decline.
Adjusting for age at baseline, age left formal education, gender, ethnicity and baseline
MMSE the model with lowest AIC included HoNOS items for behavioral disturbance, non-
Disease progression trajectories in dementia
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Table 1. Summary statistics from the latent class growth analysis reveals six trajectory model is optimal for explaining heterogeneity in cognitive
scores.
k specified iter k logLik AIC BIC EIC BLRT p value
1 2 1 -55682.86 111373.72 111404.78 - -
2 21 2 -51276.39 102570.78 102640.67 0.85 0.1
3 61 3 -49669.02 99366.04 99474.76 0.84 < 0.01
4 44 4 -49002.06 98042.12 98189.67 0.79 < 0.01
5 204 5 -48702.54 97453.08 97639.45 0.76 < 0.01
6 48 6 -48466.82 96991.63 97216.83 0.75 0.00399
7 92 7 -48336.27 96740.53 97004.56 0.71 0.0549
8 84 7 -48336.27 96740.55 97004.57 0.71 0.323
9 216 9 -48081.15 96250.3 96591.99 0.68 0.123
10 166 9 -48114.76 96317.51 96659.2 0.68 0.540
k = number of latent classes, iterations = number of iterations before convergence, logLik = logliklihood, AIC = Akaike Information Criterion, BIC = Bayesian
Information Criterion, EIC = Entropy Information Criterion, BLRT = Boostraped Likelihood Ratio Test
https://doi.org/10.1371/journal.pone.0178562.t001
Fig 1. Six trajectories optimally explain the heterogeneity in cognitive decline in this SLaM NHS Trust
patient sample with at least three MMSE scores. The trajectories show trend of lower initial baseline
MMSE score and faster rate of decline. Trajectory 4 is distinct in that is has a similar baseline MMSE score to
trajectory 3 but a similar rate to that of trajectory 6.
https://doi.org/10.1371/journal.pone.0178562.g001
Disease progression trajectories in dementia
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Fig 2. Six trajectories identified in the latent class growth analysis with estimated profile and individual level MMSE
profiles. Trajectory 1 (A) to Trajectory 6 (F).
https://doi.org/10.1371/journal.pone.0178562.g002
Disease progression trajectories in dementia
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accidental self-injury, cognitive problems, other mental and behavioral problems and ADL
and medications; donepezil, amlodipine, fluoxetine, sertraline and olanzapine (Fig 3, Table 3).
No evidence of collinearity was observed between these covariates.
Relative risk ratios (RRR) for the association of covariates with membership to each trajec-
tory can be found in Table 3. We focus on describing the differences between trajectories 3
and 4, which have different rates of decline, but very similar baseline MMSE scores estimated
by the model (trajectory 3: mean = 22.2 (standard error (SE) = 0.09) and trajectory 4:
mean = 21.8 (SE = 0.24)), suggesting these subjects were mild cognitively impaired at baseline
[29, 30].
Subjects in trajectory 3, the slower trajectory, were slightly older than trajectory 4 (RRR = 1.03,
95% CI = 1.002–1.05) (Fig 3, Table 3). They were more likely to be rated as mild for the HoNOS
cognitive problems item (RRR = 2.71, 95% CI = 1.45–5.06), the level indicating a requirement for
intervention. These subjects were also less likely to have moderate/severe behavioral disturbances
(RRR = 0.26, 95% CI = 0.12–0.56) and less likely have been prescribed sertraline (RRR = 0.44,
95% CI = 0.23–0.83) than trajectory 4. Trajectory 3 individuals were however, more likely to have
had moderate/severe other mental health and behavioral problems (RRR = 2.02, 95% CI = 1.11–
3.68) (Fig 3, Table 3).
In a sensitivity analysis, weighting each individual by class membership probability, fewer
variables are selected into the model. These include HoNOS items for cognitive problems,
Donepezil, Sertraline and Fluoxetine. We see comparable associations of variables with mem-
bership to trajectories 3 and 4 where included (S7 Table).
Predicting trajectory membership
We tested the ability of baseline characteristics to predict membership to the faster declining
trajectory 4, over trajectory 3.
Table 2. Trajectory parameter estimates for six-trajectory latent class growth model.
Trajectory Parameter Estimate SE z value p value
1 Intercept 27.9 0.0648 431 < 2.2e-16
time (years) -0.199 0.0446 -4.45 8.54E-06
time2 (years) -0.0122 0.0211 -0.580 0.562
2 Intercept 24.9 0.09051 262 < 2.2e-16
time (years) -0.469 0.0592 -7.92 2.37E-15
time2 (years) -0.127 0.03 -4.25 2.16E-05
3 Intercept 21.5 0.129 167 < 2.2e-16
time (years) -0.841 0.0727 -11.6 < 2.2e-16
time2 (years) -0.166 0.0376 -4.42 9.69E-05
4 Intercept 18.7 0.340 55 < 2.2e-16
time (years) -2.53 0.211 -12 < 2.2e-16
time2 (years) 0.140 0.114 1.23 0.219
5 Intercept 17.3 0.163 106 < 2.2e-16
time (years) -1.37 0.113 -12.2 < 2.2e-16
time2 (years) -0.175 0.0533 -3.29 0.000985
6 Intercept 11.4 0.183 62.2 < 2.2e-16
time (years) -2.81 0.124 -22.6 < 2.2e-16
time2 (years) 0.289 0.0846 3.42 0.000631
SE = standard errors, time2 = time squared
https://doi.org/10.1371/journal.pone.0178562.t002
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The radial SVM model was selected, as it was a more parsimonious model, with fewer pre-
dictors than both the linear and polynomial model, but similar training accuracy. This model
had an optimal sigma of 0.039 and contained 7 predictors including baseline MMSE, age, ser-
traline prescription and citalopram prescription. Binary variables for HoNOS items mild cog-
nitive problems, mild physical illness or disability and mild problems with other mental health
or behavioral problems were also included. On the test set, an accuracy of 0.79 (95% CI 0.73–
0.85), sensitivity and specificity of 0.42 and 0.94, respectively and AUC of 0.76 was achieved.
Here the accuracy is high, but misleading as with trajectory 4 as our positive class, the low sen-
sitivity suggests a preference for classifying individuals to trajectory 3 (Table 4).
Diagnosis across trajectories
Of those studied, 78% received one or more type of dementia diagnosis, 33% received one or
more type of other mental health diagnosis and 18% of subjects received both a dementia and
another mental health diagnosis (Fig 4A). MCI is included in the proportion of individuals
diagnosed with dementia to reflect the uncertainty of diagnosis but suggestive evidence of path
Fig 3. Forest plot of relative risk ratios (RRR) and confidence intervals for baseline characteristics of
trajectory 3 compared to trajectory 4 from multinomial regression. Trajectory 3 is at lower risk of
moderate or severe behavioral disturbances and Sertraline prescription (RRR <1), is older and at higher risk
of mild cognitive problems and moderate or severe other mental health and behavioral difficulties (RRR > 1)
than trajectory 4. RRR of 1 indicate no difference between trajectories. Confidence intervals including 1 are
non-significant.
https://doi.org/10.1371/journal.pone.0178562.g003
Disease progression trajectories in dementia
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Table 3. Multinomial regression relative risk ratios highlight key differences in characteristics between each trajectory and trajectory four.
1 vs 4 2 vs 4 3 vs 4 5 vs 4 6 vs 4
RRR 95% CI RRR 95% CI RRR 95% CI RRR 95% CI RRR 95% CI
Age 0.94 0.91 0.98*** 0.99 0.97 1.02 1.03 1 1.05* 1.04 1.01 1.07* 1.02 0.99 1.06
Gender
Male 1.45 0.92 2.29 1.1 0.77 1.58 1.19 0.85 1.68 0.95 0.65 1.4 0.99 0.63 1.56
Ethnicity
Black 1.08 0.35 3.35 1.13 0.46 2.73 1.78 0.72 4.41 0.95 0.36 2.56 1.69 0.49 5.83
Other 1.19 0.22 6.42 0.63 0.18 2.25 0.71 0.19 2.64 1.37 0.36 5.23 1.85 0.34 9.93
White 1.17 0.44 3.14 0.97 0.44 2.13 1.42 0.63 3.2 0.81 0.33 1.97 1.23 0.39 3.89
Age Left School
15–16 0.52 0.18 1.47 0.42 0.17 1.01 0.45 0.19 1.07 0.45 0.17 1.22 0.64 0.19 2.1
16–22 0.87 0.25 2.99 0.67 0.23 1.94 0.46 0.16 1.35 0.54 0.16 1.82 0.67 0.14 3.11
7–14 0.4 0.15 1.06 0.42 0.19 0.94* 0.52 0.24 1.14 0.5 0.21 1.21 1.2 0.43 3.34
Unknown 0.36 0.15 0.86* 0.39 0.19 0.81* 0.47 0.23 0.97 0.51 0.23 1.12 0.81 0.32 2.07
Baseline MMSE score 2.66 2.37 2.99*** 1.37 1.28 1.46*** 0.95 0.9 1 0.68 0.64 0.72*** 0.51 0.47 0.55***
Behavioural
Disturbance
Minor 0.56 0.3 1.06 0.72 0.45 1.15 0.79 0.51 1.23 0.76 0.47 1.24 1.04 0.6 1.81
Mild 0.38 0.17 0.84* 0.65 0.36 1.17 0.73 0.42 1.28 0.69 0.37 1.29 0.98 0.48 1.98
Moderate or Severe 0.2 0.07 0.57** 0.29 0.13 0.64** 0.26 0.12 0.56*** 0.39 0.18 0.88* 0.66 0.27 1.6
Non-accidental self-
injury
Minor 1.84 0.68 4.93 1.03 0.45 2.34 0.97 0.43 2.17 0.98 0.39 2.44 0.47 0.15 1.45
Mild 4.12 0.72 23.72 3.7 0.79 17.22 1.5 0.3 7.58 0.97 0.14 6.51 0.34 0.03 3.63
Moderate or Severe 5.52 0.36 84.45 10.51 0.85 130.42 2.75 0.2 37.93 0.82 0.03 25.83 3.52 0.16 78.76
Cognitive Problems
Minor 1.35 0.7 2.62 1.17 0.65 2.1 1.87 0.99 3.54 2.26 0.89 5.75 10.23 2 52.29**
Mild 0.78 0.38 1.57 1.61 0.9 2.87 2.71 1.45 5.06** 4.46 1.83 10.85*** 14.68 3.03 71.27***
Moderate or Severe 0.65 0.23 1.82 0.91 0.43 1.92 1.94 0.93 4.04 6.39 2.45 16.68*** 28.26 5.59 142.78***
Other Mental
Behavioural Problems
Minor 1.95 1.07 3.57 1.22 0.76 1.96 1.32 0.84 2.08 1.21 0.73 2.02 1.15 0.63 2.1
Mild 2.21 1.19 4.10* 1.38 0.86 2.23 0.98 0.61 1.56 1.35 0.81 2.24 1.28 0.71 2.31
Moderate or Severe 3.03 1.44 6.37** 1.72 0.92 3.22 2.02 1.11 3.68* 1.45 0.72 2.9 1.44 0.65 3.2
ADL
Minor 0.5 0.28 0.89* 0.5 0.32 0.79** 0.72 0.46 1.14 0.79 0.47 1.34 0.96 0.5 1.86
Mild 0.71 0.37 1.34 0.59 0.36 0.97* 0.94 0.58 1.53 1.04 0.6 1.79 1.14 0.59 2.22
Moderate or Severe 0.41 0.18 0.92* 0.43 0.23 0.79** 0.82 0.46 1.45 0.73 0.38 1.38 1.29 0.61 2.71
Anti-Dementia
Donepezil 0.68 0.38 1.24 1 0.67 1.51 1.4 0.96 2.05 1.08 0.71 1.65 0.97 0.59 1.58
Antihypertensive
Amlodipine 1.1 0.54 2.26 1.71 0.98 2.99 1.72 1 2.97 1.86 1.02 3.37 2.09 1.06 4.11*
Antidepressants
Fluoxetine 4.82 1.15 20.16* 1.5 0.47 4.76 1.02 0.33 3.13 0.43 0.1 1.8 0.64 0.14 2.96
Sertraline 0.7 0.31 1.56 0.51 0.27 0.98 0.44 0.23 0.83* 0.41 0.19 0.85* 0.22 0.09 0.58**
Antipsychotics
Olanzapine 1.73 0.73 4.09 0.77 0.36 1.62 0.79 0.38 1.67 0.38 0.14 1.07 0.44 0.13 1.49
RRR Relative Risk Ratio from multinomial regression analysis. CI Confidence Interval, *p 0.05, **p 0.01, ***p 0.001
https://doi.org/10.1371/journal.pone.0178562.t003
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to dementia. 63.8% of individuals with MCI diagnosis receive at least one other dementia diag-
nosis during follow-up.
Across trajectories we saw significant differences in the proportion of both dementia diag-
noses (χ2-statistic = 260, p< 0.0001) and other mental health diagnoses (χ2-statistic = 201,
p< 0.0001). Trajectories 1 and 2 had the lowest proportion of subjects with dementia diagno-
ses (52% and 75%, respectively) but the highest with other mental health diagnoses (54% and
36%, respectively). Conversely, trajectories 5 and 6 have the highest proportion diagnosed with
dementia (both 87%), particularly AD and the lowest with other mental health diagnoses (21%
and 19% respectively) (Fig 4B and 4C).
The proportion of subjects with both dementia and other mental health diagnosis also dif-
fered significantly across trajectory classes (χ2-statistic = 33, p = 2.68x10-06). Trajectory 4 had
the highest proportion of subjects diagnosed with both dementia and other mental health diag-
noses (28%). It has the same rate of diagnosis of psychosis as trajectory 1 (12%) but slightly
lower prevalence of depression than trajectory 1 (37% and 24%) (Fig 4B and 4D).
Taken together, these differences reflect the degree of decline in each trajectory but do not
reflect trajectories of single dementia sub-types.
Comparing trajectories 3 and 4 specifically, trajectory 3 had a statistically significantly
smaller proportion of subjects diagnosed with MCI (14% and 21%, p = 0.0103), VD (21% and
30%, p = 0.00213) and LBD (1% and 3%, p = 0.0149) and a higher proportion diagnosed with
AD (69% and 59%, p = 0.00106) during follow up (Fig 4E). Trajectory 4 had significantly
higher proportion of subjects diagnosed with depression (26% and 20%, p = 0.0236), anxiety
(8% and 5%, p = 0.0426), psychosis (12% and 6%, p = 0.00285), and schizophrenia (6% and
3%, p = 0.0455) (Fig 4F).
Discussion
Six categories of decline best explained the variability in MMSE score trajectories in 3,441
patients from a large mental health case register, who had at least 3 MMSE scores recorded
during visits to dementia services between 2007 and 2014.
For the estimated trajectories, we generally found that the lower the baseline MMSE score,
the faster the rate of decline observed. This pattern suggests disease stage is contributing to
subject stratification for some of the trajectories. The lack of information on time since first
presentation of symptoms or a secondary measure of cognition means this study is limited to
account for individual differences in disease duration. This may be less of an issue in cohort
studies with individuals recruited pre-symptomatically, however to our knowledge the impact
of including individuals at different stages in trajectory modeling is unexplored.
Trajectories 3 and 4 had similar baseline estimated MMSE scores and are more likely to
represent the consequences of different decline trajectories rather than an artifact of the
known non-linear performance of the MMSE across dementia severity. Some interesting
observations were made in multivariable multinomial logistic regression. A higher propor-
tion of patients were rated as mild for the HoNOS cognitive problems item at baseline in tra-
jectory 3.
Table 4. Confusion matrix for classification of trajectories 3 and 4 (positive class).
Test set class
Predicted class Four Three
Four 25 9
Three 35 145
https://doi.org/10.1371/journal.pone.0178562.t004
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Fig 4. Proportions of diagnoses in the patient sample from SLaM CRIS. (A) Diagnosis types of the total sample; 78% of
subjects have at least one diagnosis of dementia, 33% of subjects have at least one other mental health diagnosis, 18% have
at least one of both dementia and other mental health diagnoses, (B) diagnosis types in each trajectory; Trajectory 1 has the
Disease progression trajectories in dementia
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It is evident that multiple co-morbidities were present in the sub-population in trajectory 4.
Subjects were more likely to be diagnosed with depression during follow up, prescribed sertra-
line at baseline and more likely to have behavioral disturbances at baseline in comparison to
all other trajectories. The cumulative effect of depressive symptoms is thought to contribute to
increased cognitive decline [12]. Observational studies and small-scale clinical trials in Alzhei-
mer’s subjects with depression and healthy older adults have not shown an effect of sertraline
on cognitive decline [31–34], suggesting it is not the medication itself which is associated with
rate of decline.
Diagnosis of psychosis and psychotic symptoms during follow up was higher in trajectory
4. Both psychosis and behavioral disturbances, agitation and aggression have been associated
with a worse rate of decline in AD [35] and subjects who develop psychosis in AD may experi-
ence greater cognitive impairment[36].
The contribution of physical health co-morbidities was not explored in this study but may
associate with rate of decline in dementia. Indeed, there is some evidence for an association of
hypertension and cognitive decline in middle-aged individuals[37] and suggestive evidence for
faster decline in subjects with both type 2 diabetes and MCI or AD diagnosis, although sample
sizes for this group is small[38].
We explored whether it is possible to predict membership to the faster declining trajectory
using information at baseline. Feature selection incorporates sertraline (as a possible surrogate
for depression), suggested to be more likely to be prescribed in trajectory 4, mild HoNOS cog-
nitive problems item (fewer in trajectory 4), age (trajectory 4 slightly younger than trajectory
3) and baseline MMSE, although only a small difference in mean score exists. Other selected
predictors were mild other mental health or behavioral problems (less likely in trajectory 4),
mild physical illness or disability and citalopram prescription, both more likely in trajectory 4.
Interestingly no information on behavioral difficulties was selected, although multinomial
analysis suggests subjects in trajectory 4 are more likely to have behavioral disturbances.
Whilst the model accuracy on the test set is in an acceptable range, the sensitivity is low sug-
gesting many false negatives are possible i.e. subjects who will decline more rapidly being clas-
sified to the slower declining trajectory. Increasing the sensitivity would reduce false negatives
at the cost of increasing false positives. The preference of false negative and false positive rates
would depend on the clinical implications for patients being classified to the faster declining
trajectory.
This difficulty in predicting membership to trajectory 4 suggests we may be missing a
covariate with predictive importance. Indeed it was not possible to investigate APOE e4 status,
Amyloid and Tau protein information. These variables should be explored in future studies.
Inclusion of individuals is based on 3 MMSE scores, reflecting individuals being monitored
for dementia. This leaves the possibility to study individuals early in disease or who do not
develop dementia during study follow up. In our analysis, these individuals are largely classi-
fied to Trajectory 1. Despite the lack of change for this trajectory, some individuals receive a
highest proportion with other mental health diagnosis and lowest with dementia. Conversely, trajectories 5 and 6 have the
highest proportion with dementia diagnoses and lowest with other mental health diagnoses. Trajectory 4 has the highest
proportion of subjects with both dementia and other Mental Health diagnoses. (C) Dementia diagnoses in each trajectory;
each dementia diagnosis differs significantly in proportion across trajectory classes, with the exception of FTD and
Parkinson’s (p < 0.05) (D) Other mental health diagnoses in each trajectory; all diagnoses differ significantly across trajectory
classes with the exception of bipolar and behavioral diagnoses. (E) Comparison of dementia diagnosis in trajectories 3 and 4;
significantly lower proportion of subjects with Alzheimer’s diagnosis, but higher proportion of VD, MCI and LBD diagnoses in
trajectory 4. (F) Comparison of other mental health diagnoses in trajectories 3 and 4; significantly higher proportion of
subjects with depression, anxiety, psychosis and schizophrenia in trajectory 4.
https://doi.org/10.1371/journal.pone.0178562.g004
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dementia diagnosis during follow-up. This could be related to misdiagnosis or misclassifica-
tion of individuals to trajectory 1.
Variability in diagnosis method means we do not restrict our observations to dementia
diagnosis groups and are limited in our ability to study each sub-type separately due to the pos-
sibility of misdiagnosis and misclassification. Indeed, 12% of individuals have at least two dif-
ferent dementia sub-types diagnosed during follow-up, when excluding MCI as a sub-type.
This may however, reflect the progressive nature of the disease with cognitive deficits manifest-
ing differentially over time.
Studies exploring cognitive decline trajectories have identified between 3 and 8 trajectories
[39–41], differences could be attributed to modeling with different cognitive measures and
assessing decline by age instead of time. The large sample of individuals selected for this study
is representative of the population being served by SLAM. Independent replication would fur-
ther support these findings.
The MMSE, due to its use as a tool to explore cognitive impairment, is widely recorded in
health records of older adults. Further improvements in model fit may be achieved by assum-
ing a beta-binomial distribution for the MMSE scores[39]. Despite this and the floor and ceil-
ing effects of the MMSE[17, 42], this study is able to detect multiple trajectories of decline in
moderate-to-severe individuals. In addition, our associations of behavioral difficulties and
depression between these trajectory groups are consistent with our understanding of more
rapid decline previously reported.
Conclusions
This study provides evidence for multiple trajectories of decline in dementia, using real world
data from one of the largest mental healthcare providers in Europe. Despite a confounding
effect of disease stage on trajectory membership, we find that differences in behavioral distur-
bances and antidepressant medication may be informative of rate of cognitive decline in
patients with dementia.
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